The addition of rituximab to anthracycline‐based chemotherapy significantly improves outcome in ‘Western’ patients with intravascular large B‐cell lymphoma

British Journal of Haematology - Tập 143 Số 2 - Trang 253-257 - 2008
Andrés J.M. Ferreri1, Giuseppina Dognini1, Osnat Bairey2, Árpád Szomor3, Carlos Montalbán4, Barbara Horváth5, Judit Demeter6, L. Uziel7, Riccardo Soffietti8, John F. Seymour9, Achille Ambrosetti10, Rein Willemze11, Maurizio Martelli12, Giuseppe Rossi13, Anna Candoni14, Amalia De Renzo15, Claudio Doglioni16,1, Emanuele Zucca17, Franco Cavalli17, Maurilio Ponzoni16,1
1Unit of Lymphoid Malignancies and Medical Oncology Unit, Department of Oncology, San Raffaele H Scientific Institute, Milano, Italy
2Division of Haematology, Rabin Medical Centre, Beilinson Hospital, Petah Tiqwa, Israel
3First Department of Medicine, University of Pecs, Pecs, Hungary
4Servicio de Medicina Interna, Hospital Ramón y Cajal, Madrid, Spain
5Department of Dermato-venereology and Dermato-oncology, Budapest, Hungary
6First Department of Medicine, Semmelweis University, Budapest, Hungary
7Division of Haematology, Ospedale San Paolo, Milan, Italy
8Division of Neuro-oncology, Department of Neuroscience, University and San Giovanni Battista Hospital, Turin, Italy
9Australasian Leukaemia and Lymphoma Group and Univ. of Melbourne, Australia
10Dipartimento di Medicina Interna e Sperimentale, Sezione di Ematologia, Università di Verona, Verona, Italy
11Dutch Cutaneous Lymphoma Group, Leiden, The Netherlands
12Division of Haematology, Università La Sapienza, Rome, Italy
13Division of Hematology, Spedali Civili di Brescia, Italy
14Policlinico Universitario, Udine, Italy
15Division of Hematology, Università Federico II, Napoli, Italy
16Pathology Unit, San Raffaele H Scientific Institute, Milan, Italy
17Division of Medical Oncology, Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland

Tóm tắt

SummarySome case reports and a Japanese series suggest benefit from the use of rituximab in patients with intravascular large B‐cell lymphoma (IVL). Rituximab efficacy was evaluated in Western patients with IVL, comparing outcome of 10 patients treated with rituximab + chemotherapy (R‐CT) and of 20 patients treated with chemotherapy alone (CT). There were no significant differences in patients’ characteristics between the two subgroups. The addition of rituximab was associated with improved complete remission rate (90% vs. 50%; P = 0·04), event‐free survival (3‐year: 89% vs. 35%; P = 0·003) and overall survival (3‐year: 89% vs. 38%; P = 0·01). In conclusion, rituximab may substantially change the dismal prognosis of IVL.

Từ khóa


Tài liệu tham khảo

10.1056/NEJMoa011795

10.1111/j.1365-2141.2004.05177.x

10.1093/annonc/mdh274

10.3324/haematol.10829

10.1097/01.coc.0000182463.57861.3c

10.1200/JCO.1999.17.12.3835

10.1111/j.1440-1827.2004.01613.x

10.3109/10428199909058451

10.1200/JCO.2006.08.2313

10.1200/JCO.2007.15.4278

10.3324/haematol.10561

Thông tin
Thông tin xuất bản

British Journal of Haematology

Tập 143 Số 2

253-257

Thông tin tác giả